Keyphrases
Newly Diagnosed
100%
Peripheral T-cell Lymphoma
100%
Phosphoinositide 3-kinase (PI3K)
20%
Improved Outcomes
20%
Chemotherapy
20%
5-year Survival
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Positron Emission Tomography-computed Tomography (PET-CT)
20%
Non-Hodgkin Lymphoma
20%
Disease Response
20%
Clinical Practice
20%
Aggressive B-cell Lymphoma
20%
Patient Mortality
20%
Conventional Therapy
20%
Leukemia-lymphoma
20%
Interim PET-CT
20%
Etoposide
20%
Acute T-cell Leukemia
20%
In Care
20%
Disease Monitoring
20%
Kinase Inhibitor
20%
Brentuximab Vedotin
20%
Success Strategies
20%
Mogamulizumab
20%
Cell-free DNA (cfDNA)
20%
Hypomethylating Agents
20%
Histology-agnostic
20%
Mutational Profiling
20%
CD30 Positive
20%
Multiple Attempts
20%
Histone Deacetylates
20%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
CHOP
40%
Positron Emission Tomography-Computed Tomography
20%
Histone
20%
Non-Hodgkin Lymphoma
20%
B-Cell Lymphoma
20%
Stem Cell Transplant
20%
Adult T-Cell Leukemia/Lymphoma
20%
Prognostication
20%
Etoposide
20%
Phosphotransferase Inhibitor
20%
Brentuximab Vedotin
20%
Mogamulizumab
20%
Hypomethylating Agent
20%
Inositol Phosphate
20%
Cell-Free DNA
20%
Diseases
20%